Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 449Neoplasms, Plasma Cell 69Recurrence 42Immunoglobulin Light-chain Amyloidosis 24Neoplasms 12Paraproteinemias 9Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hematologic Neoplasms 9Renal Insufficiency 8Amyloidosis 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Lymphoma 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Plasma Cell 6Leukemia, Myeloid, Acute 6Hematologic Diseases 6Waldenstrom Macroglobulinemia 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia 5Burkitt Lymphoma 5Immunoproliferative Disorders 4Hodgkin Disease 4Blood Protein Disorders 4Plasmacytoma 3Peripheral Nervous System Diseases 3Neoplasms by Histologic Type 3

Interventions

Lenalidomide 2Dexamethasone 2Bortezomib 2carfilzomib 1belinostat 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bone Marrow Neoplasms × Bortezomib × Plasma cell × Clear all
NCT01286077 2016-05-30

Velcade Consolidation Bone Study

Janssen-Cilag International NV

Phase 2 Completed
106 enrolled 19 charts
Plasma cell

Multiple Myeloma, Bone Marrow Neoplasms

NCT00908232 2015-01-15

SEQUENTIAL

Janssen-Cilag International NV

Phase 2 Completed
163 enrolled 11 charts
Plasma cell

Multiple Myeloma, Disease Progression, Bone Marrow Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡